Recombinant Human Active MEK2 Protein, CF

R&D Systems | Catalog # 2855-KS

R&D Systems
100% Guarantee

Key Product Details

  • R&D Systems Sf 9 (baculovirus)-derived Recombinant Human Active MEK2 Protein (2855-KS)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

Sf 9 (baculovirus)

Accession Number

NM_030662

Applications

Bioactivity
View all MEK2 Proteins and Enzymes »

Product Specifications

Source

Spodoptera frugiperda, Sf 9 (baculovirus)-derived human MEK2 protein

Purity

>80%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.

N-terminal Sequence Analysis

Using an N terminal GST tag

SDS-PAGE

71 kDa

Activity

The specific activity of MEK2 was determined to be 190 nmol/min/mg in a coupled assay using an ERK2 substrate and a myelin basic protein (MBP) substrate.

Reviewed Applications

Read 1 review rated 4 using 2855-KS in the following applications:

Scientific Data Images for Recombinant Human Active MEK2 Protein, CF

Recombinant Human Active MEK2 Protein SDS-PAGE

Recombinant Human Active MEK2 Protein SDS-PAGE.

The approximate molecular weight is 71 kDa and the purity is > 80%.

Formulation, Preparation, and Storage

2855-KS
Formulation Supplied in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage This product is stable at ≤ ‑70°C for up to 1 year from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature. Avoid repeated freeze-thaw cycles.

Background: MEK2

MEK2 is the member of MAPK kinase (MAPKK) family of signaling protein kinases. MEK2 is a dual-specificity kinase that activates the extracellular signal-regulated kinase (ERK) and mitogen-activated protein (MAP) kinase upon agonist binding to receptors. MEK2 plays a key role in the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathways (1). Approximately 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK2 results in cellular transformation. The ERK/MAP kinase cascade regulates cell growth and differentiation (2).

References

  1. Shuichan, X. et al. (1997) Mol. Endocrinol. 11:1618.
  2. Louis-François, B. et al. (2003) Mol. Cell. Biol. 23:4778.

Long Name

Mitogen-activated Protein Kinase Kinase 2

Alternate Names

MAP2K2, MKK2

Entrez Gene IDs

5605 (Human); 26396 (Mouse)

Gene Symbol

MAP2K2

UniProt

NM_030662

Additional MEK2 Products

Product Documents for Recombinant Human Active MEK2 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Active MEK2 Protein, CF

For research use only

Customer Reviews for Recombinant Human Active MEK2 Protein, CF (1)

4 out of 5
1 Customer Rating
5 Stars
0%
4 Stars
100%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Recombinant Human Active MEK2 Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card
Showing  1 - 1 of 1 review Showing All
Filter By:
Clear Filters X
  • Recombinant Human Active MEK2 Protein, CF
    Name: Balaji Mahender
    Application: Immunoassay Standard
    Verified Customer | Posted 02/26/2018

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All

Protocols

View specific protocols for Recombinant Human Active MEK2 Protein, CF (2855-KS):

Materials
  • Active Kinase - Active MEK2 (0.1 μg/μL) diluted with Kinase Dilution Buffer. Note: These are suggested working dilutions. Optimal dilutions should be determined by each laboratory for each application.
  • Kinase Assay Buffer I - 25 mM MOPS, pH 7.2, 12.5 mM beta -glycerolphosphate, 25 mM MgCl2, 2 mM EDTA. Add 0.25 mM DTT to the Kinase Assay Buffer prior to use.
  • Kinase Dilution Buffer - Kinase Assay Buffer diluted at a 1:4 ratio (5X dilution) with 50 ng/μL BSA solution.
  • 10 mM ATP Stock Solution - Prepare the ATP Stock Solution by dissolving 55 mg of ATP in 10 mL of Kinase Assay Buffer. Store 200 μL aliquots at ≤ -20 °C.
  • [33P]-ATP Assay Cocktail - Prepare 250 μM [33P]-ATP Assay Cocktail in a designated radioactive work area by combining 150 μL of 10 mM ATP Stock Solution, 100 μL of [33P]-ATP (1 mCi/100 μL), and 5.75 mL of Kinase Assay Buffer. Store 1.0 mL aliquots at ≤ -20 °C.
  • Substrate - Inactive ERK2 was activated using MEK2 and a Myelin Basic Protein (MBP) diluted in 100 mM MOPS, pH 6.5 buffer to a final concentration of 0.2 mg/mL and 1.0 mg/mL, respectively.
  1. Thaw the Active MEK2, Kinase Assay Buffer I, and inactive ERK2 on ice. In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20 μL.
    a. Diluted Active MEK2: 5 μL
    b. Inactive ERK2 (0.2 μg/μL): 10 μL
    c. Kinase Assay Buffer: 5 μL
  2. Start the reaction with the addition of 5 μL ATP (250 μM) and incubate in a water bath at 30 °C for 15 minutes.
  3. After the 15 minute incubation, remove 5 μL and add it to the following reaction components on ice, bringing the initial reaction volume up to 20 μL
    a. Reaction Mixture: 5 μL
    b. MBP Substrate (1 mg/mL; on ice): 5 μL
    c. Distilled or deionized water (on ice): 10 μL
  4. Set up the blank control as outlined in step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled or deionized water.
  5. Thaw the [33P]-ATP Assay Cocktail in a shielded container in a designated radioactive work area. Initiate the reaction with the addition of 5 μL [33P]-ATP Assay Cocktail, bringing the final volume up to 25 μL. Incubate the mixture in a water bath at 30 °C for 15 minutes.
  6. After the 15 minute incubation, terminate the reaction by spotting 20 μL of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
  7. Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (add 10 mL of phosphoric acid to 990 mL of distilled or deionized water) with constant gentle stirring. It is recommended that the strips be washed a total of three times for approximately 10 minutes each.
  8. Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
  9. Determine the corrected cpm by subtracting the blank control value (see step 4) for each sample and calculate the kinase specific activity as outlined below:


    Calculation of [33P]-ATP Specific Activity (SA) (cpm/pmol)
    Specific Activity (SA) = cpm for 5 μL [33P]-ATP/pmol of ATP (in 5 μL of a 250 μM ATP stock solution; i.e. 1250 pmol)

    Calculation of Kinase Specific Activity (SA) (pmol/minutes/μg or nmol/minutes/mg)
    Corrected cpm from reaction / [(SA of 33P-ATP in cpm/pmol) x (Reaction time in minutes) x (Enzyme amount in μg or mg)] x [(Reaction volume) / (Spot Volume)]

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes